were used to calculate the summary statistics we presented, have been changed. In this addendum, we publish new reference statistics using the WHO 2006 TEFs in addition to assessing the effect of these new TEFs on total TEQ concentrations for the general US population. We also examined the effect of the limits of detection (LODs) on the calculated TEQ summary statistics for the top seven contributing congeners and completed a missing data analysis to determine whether our estimates were biased by excluding individuals without complete congener profiles. Similar to our previous results, 2, 3, 7, 1, 2, 3, 7, 1, 2, 3, 6, 7, 2, 3, 4, 7, and PCB 126 contributed the most to total TEQ. However, both PCB 156 and 157 were no longer significant contributors, instead being displaced by 1, 2, 3, 4, 7, 8-HxCDF, and PCB 169. In general, the decrease in TEFs for the mono-ortho-substituted PCBs decreased their contribution to total TEQ appreciably, causing TEQ 17-9 to approximately equal TEQ 17-3 . The effect of LODs for five of the top seven contributing congeners was negligible; however, the LODs for 2, 3, 7, 8-TCDD and 1, 2, 3, 7, 8-PeCDD were noticeably higher and may impact TEQ estimates primarily for individuals aged 20-29 years. Results from the missing data analysis provide compelling evidence that the summary statistics we reported previously, as well as those described here, were not greatly influenced due to censoring data.
Introduction
The availability of serum concentration reference values has become essential as biomonitoring data are being used more often to determine if individuals have been exposed to specific chemicals (NRC, 2006; Paustenbach and Galbraith, 2006a, b) . In our original paper (Ferriby et al., 2007) , we described serum reference concentrations of polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and dioxin-like polychlorinated biphenyls (PCBs) for the general US population using the 1998 World Health Organization (WHO) Toxic Equivalency Factors (TEFs) and dioxin-like serum concentration data from the 2001-2002 National Health and Nutrition Examination Survey (NHANES). TEFs, initially developed in the mid-1980s to facilitate the evaluation of potential health risks associated with exposure to complex mixtures of PCDD/Fs and PCBs, have been revised multiple times over the past 20 years based on advances in the state of the science . Prior to publication of our original report, a WHO International Programme on Chemical Safety (IPCS) expert panel was convened to re-evaluate the contemporaneous TEFs. In July 2006, Van den Berg et al. published revised TEFs for 2, 3, 4, 7, 1, 2, 3, 7, octachlorodibenzofuran; and PCBs 81 and 169 , along with all mono-ortho substituted PCBs.
In accordance with these changes, we reanalyzed the 2001-2002 NHANES serum concentration data for PCDDs, PCDFs, and dioxin-like PCBs, and, using the revised WHO 2006 TEFs, calculated reference statistics for the general population. In this addendum, we present the updated summary statistics for several demographic subgroups, along with an assessment of the contribution of individual congeners to the total TEQ. For completeness, we evaluated the effect the revised TEFs had on total TEQ serum concentrations, in addition to the effect of the limits of detection (LODs) on the calculated TEQ summary statistics for the top seven congeners. Additionally, we conducted a missing-data analysis to assess whether excluding individuals without complete congener data impacted our estimates.
Methods

Data Source
Data collection and laboratory analytical techniques have been described formerly (NCHS, 2005a; Ferriby et al., 2007) . Further details regarding the NHANES procedures, survey components, questionnaires, and examination are available at the CDC National Center for Health Statistics website, http://www.cdc.gov/nchs/nhanes.htm. Serum concentrations of all 2, 3, 7, 8-substituted PCDD/Fs, as well as PCBs 81, 105, 118, 126, 156, 157, 167, 169, and 189 , were quantified in this study. Analytes were measured using high-resolution gas chromatography and/or isotope-dilution high-resolution mass spectrometry (HRGS/ID-HRMS) as described in the Third National Report on Human Exposure to Environmental Chemicals (NCHS, 2005b) . All samples with concentrations below the LOD were assumed to have a concentration equivalent to the proxy value assigned by the CDC, which is equal to the sample-specific LOD divided by the square root of 2 (C ND ¼ LOD/O2).
Statistical Analysis
Statistical analysis methods used in this study have been described previously by Ferriby et al. (2007) . Briefly, lipid-adjusted PCDD, PCDF, and PCB serum concentration data from the NHANES 2001-2002 survey were linked to gender, race, smoking status, and age demographics using the unique survey participant identifier assigned to each subject. Only data from participants with complete PCDD/F and PCB profiles were selected for analysis. PCDD/F and PCB TEQs for individual subjects were calculated by summing the product of each congener's concentration and the associated WHO 2006 TEF ( Van den Berg et al., 2006) .
Total TCDD TEQs were calculated for four different data subsets. The first two, TEQ PCDD/F and TEQ PCB , were determined using only the contributions from the 17 PCDD/ F or nine PCB congeners that the CDC measured, respectively. The third, TEQ 17-9 , was calculated using contributions from all 17 PCDD/F congeners plus all nine PCB congeners, whereas the fourth, TEQ 17-3 , used contributions from all 17 PCDD/F congeners plus the three coplanar PCB congeners (PCBs 81, 126, and 169) . TEQ concentrations were characterized by gender, race, smoking status, and age. In accordance with the guidelines provided by the National Research Council's Committee on Human Biomonitoring for Environmental Toxicants (NRC, 2006) , weighted summary statistics, including mean, geometric mean, and 75th, 90th, and 95th percentiles, were calculated using the dioxin subset-specific 2-year weights included in the NHANES dioxin data file (NCHS, 2005a) and using SYSTAT 11.0. Ninety-five percent (95%) confidence intervals for weighted mean TEQ levels and standard errors for geometric means were calculated using SUDAAN 9.0. The average percent contribution of each congener to the total TEQ was calculated by averaging the percent contribution of that congener to the total TEQ across all subjects.
Missing-Data Analysis
We tested the robustness of various estimates using both WHO 1998 and WHO 2006 TEFs to assess whether excluding individuals without complete congener profiles biased results we reported previously (Ferriby et al., 2007) as well as the summary statistics presented here. Of the 1693 adult (i.e., 20 years and older) NHANES participants for whom serum data were analyzed, 1081 had complete congener profiles, 163 had data for one to nine congeners, 305 individuals had missing data for all 17 PCDD/F congeners, and 144 individuals had missing data for all 26 dioxin-like congeners. The latter two groups were excluded from this analysis because these individuals had missing data (due to laboratory QA/QC problems) for the majority of congeners (between 65% and 100%), making it difficult to accurately impute values. Using data from individuals with complete congener profiles, the average percent contributions for the TEQ PCDD/F and TEQ 17-9 sums were calculated with both WHO 1998 and WHO 2006 TEFs. Total TEQ concentrations for the 163 individuals missing between one and nine congeners were subsequently imputed using Eq. (1), and the TEQ of individual missing congeners was determined using Eq. (2). 
Results
Descriptive Statistics
Summary statistics for the four data subsets, TEQ PCDD/F , TEQ PCB , TEQ 17-9 , and TEQ 17-3 , are presented by gender, age, race, and smoking status in Table 1a -d. Consistent with the results of our first study (Ferriby et al., 2007) , an increasing trend in mean total TEQ was observed with increasing age such that individuals 20-29 years had average levels that were approximately one-third of those for the oldest group. As before, higher total TEQ body burdens were also noticed for non-Hispanic Blacks and Whites relative to individuals of Hispanic origin and those categorized as ''Other Race''. Table 2a -d presents the results for gender stratified by age and smoking status, and for smoking status stratified by age. Even after adjusting for gender and smoking status, the increasing trend with age was very evident, again suggesting age as a dominant predictor of body burden. However, as observed in our previous study (Ferriby et al., 2007) , both smoking status and gender influenced concentrations in the oldest individuals. Indeed, whereas non-smokers 60 years and older had three times the concentration of non-smokers of 20-29 years, those individuals 60 years and older who were smokers had only twice the body burden as smokers 20-29 years old. Collectively, these results confirm the existence of a complex interaction between age, smoking status, gender, and total TEQ serum levels.
Percent Contribution to Total TEQ
The percent contribution of the four main classes of congeners, PCDDs, PCDFs, coplanar PCBs, and monoortho PCBs, to the total TEQ 17-9 was 59%, 18%, 18%, and 5%, respectively. Similar to results in our previous study (Ferriby et al., 2007), 2, 3, 7, 8-TCDD; 1, 2, 3, 7, 8-PeCDD; 1, 2, 3, 6, 7, 8-HxCDD; 2, 3, 4, 7, 8-PeCDF; and PCB 126 still contributed the most to total TEQ, accounting for 68% of the total TEQ 17-9 (Figure 1 ). However, both PCBs 156 and 157 were no longer significant contributors, instead being displaced by 1, 2, 3, 4, 7, 8-HxCDF and PCB 169, which accounted for another 6% of the total TEQ (Figure 1) .
Overall, these results demonstrate that the effects the WHO 2006 TEFs had on total body burden are consistent with the change in scale of the TEF approach. For example, the decrease in TEFs for the mono-ortho-substituted PCBs has appreciably decreased their contribution to total TEQ from 28% to 5%, whereas the increase in the TEF for PCB 169 amplified the contribution of this congener from 0.8% to 3%. The changes in contribution observed with WHO 2006 TEFs are also apparent when comparing results presented in Table 1c and d in our original paper (Ferriby et al., 2007) with those in Table 1c and d of this report. Using WHO 2006 TEFs, TEQ 17-9 was approximately equal to TEQ 17-3 , which was further evidenced by the finding that, on average, mean total TEQ 17-9 and mean total TEQ 17-3 were 31% and 25% higher than mean total TEQ PCDD/F , respectively. This is in contrast to the findings presented in our previous publication where we reported that mean total TEQ 17-9 was 64% higher than mean total TEQ PCDD/F , whereas mean total TEQ 17-3 was only 21% higher (Ferriby et al., 2007) . Differences in TEQs resulting from changes to the TEFs were also observed within groups; however, these differences were more evident in groups with higher serum levels than in groups with lower levels. For example, serum TEQ 17-9 concentrations for individuals 60 years and older were reduced from 50.9 to 38.9 p.p.t., whereas those for individuals 20-29 years old dropped from 18.5 to 13.5 p.p.t.
Impact of LODs on Reference Values
As illustrated in Figure 2 , five of the top seven congeners, 1, 2, 3, 6, 7, 2, 3, 4, 7, 1, 2, 3, 4, 7,  and PCBs 126 and 169, had greater than 65% of samples with concentrations above the LOD, thus reducing the impact these congeners' detection limits had on the total calculated TEQ. Additionally, these five congeners also had low average LODs (Figure 2 ), thereby further minimizing the impact of the LOD for these congeners on the total TEQ. In contrast, both 2, 3, 7, 8-TCDD and 1, 2, 3, 7, 8-PeCDD had low percentages of samples, 13% and 35%, respectively, with concentrations above the LOD. Because these congeners contributed appreciably to total TEQ and their average LODs were higher than the other congeners (2.7 and 2.8 pg/g Addendum to Ferriby et al., 2007 Scott et al. lipid, respectively), they are more likely to impact TEQ estimates, primarily for younger individuals (i.e., less than 30 years of age), as they have the highest percentage of nondetected results (Ferriby et al., 2007) . Although it is doubtful that these LODs would result in considerable overestimation of total TEQ 17-9 levels for individuals 20-29 years old, the application of the descriptive statistics presented here for interpreting biomonitoring results of younger individuals should be conducted with discretion and these limitations acknowledged. Maximum values presented are not intended to represent the maximum level in the general US population, but simply indicate the maximum concentration measured for NHANES participants. Maximally exposed individuals (i.e., people living near industrial sources of PCDD/Fs and PCBs or occupationally exposed people) were not intentionally sampled in accordance with the NHANES sampling strategy.
Impact of Excluding Individuals without Complete Congener Profiles
A total of 1693 NHANES participants 20 years and older were included in the dioxin subsample, with 449 individuals missing all 17 PCDD/F congeners. Of these 449 participants, 144 individuals had missing data for all 26 congeners (17 PCDD/Fs and 9 PCBs) and 305 individuals had missing data for all 17 PCDD/Fs but had serum data for the nine PCBs.
Separately, a total of 163 individuals had missing data for one or more congeners, with the number of congeners missing ranging from one to nine. Specifically, there were 74 individuals missing data for one congener, 36 missing data for two, 14 missing data for three, 6 missing data for four, 11 missing data for five, 11 missing data for six, 5 missing data for seven, 3 missing data for eight, and 3 individuals missing data for nine congeners. When data were reanalyzed to include the 163 individuals who had data missing for between one and nine congeners (n ¼ 1244), the average percent difference in the mean and 95th percentile TEQ PCDD/F was 3. 4% and 3.3%, respectively, using WHO 1998 TEFs, and 3.2% and 3.5%, respectively, using WHO 2006 TEFs (Figure 3a) . For TEQ , the average percent difference in mean and 95th percentile estimates was 2.6% and 3.0% (WHO 1998 TEFs), respectively, and 2.4% and 1.9% (WHO 2006 TEFs), respectively ( Figure 3b) . Evaluation of differences in estimates for specific subgroups revealed that only 95th percentile values were noticeably impacted by including the 163 participants with imputed concentrations. In particular, 95th percentile TEQ values (WHO 1998 and WHO 2006 TEFs) for males aged 20-29 years were underestimated by between 12.3% and 26.6%, whereas TEQ PCDD/F estimates (WHO 1998 TEFs) for males aged 60 þ years and females aged 30-44 years, and TEQ 17-9 estimates (WHO 2006 TEFs) for males 44-59 years, were underestimated by B11%. In spite of this, 95th percentile TEQ PCDD/F and TEQ estimates presented both here and by Ferriby et al. (2007) never varied, on average, by more than 1.3 and 1.2 p.p.t., respectively (Figures 3a and b) .
Overall, the results of our missing-data analysis suggest that the TEQ estimates presented by Ferriby et al. (2007) and in this paper may have been (e.g., estimates would only be 2, 3, 7, 1, 2, 3, 7, 1, 2, 3, 6, 7, 2, 3, 4, 7, and 1, 2, 3, 4, 7, 8 -HxCDF collectively accounted for 62% of the total TEQ 17-9 , whereas 18% of the total TEQ 17-9 was attributable to PCBs 126 and 169. As a result of the changes in TEFs, both PCBs 156 and 157 were no longer significant contributors to total TEQ 17-9 . *TEF revised in 2006. underestimated if there were no other underlying analytical problems with the individuals that have missing data) slightly underestimated, but not considerably biased, by excluding individuals without complete congener profiles. Indeed, in underestimating 95th percentile concentrations, we have, to some extent, provided reasonably conservative reference values for assessing exposure to the dioxin-like compounds.
Discussion
Over the past several decades, biomonitoring has been increasingly utilized by a variety of industrial and manufacturing businesses, as well as governmental agencies, to assist in evaluating the potential exposure of particular populations to a wide range of chemicals. The benefits of biomonitoring, nonetheless, are severely limited if data cannot be interpreted. Certainly, interpretation of biomonitoring data and use of these data as an exposure-assessment tool involve understanding how the concentration of a particular chemical in an exposed individual compares with its concentration in the general population (NRC, 2006) . To that extent, the descriptive statistics provided by our analyses of the NHANES data will prove useful when evaluating the PCDD/F and PCB serum concentrations of individuals or populations potentially exposed to these compounds. Indeed, the National Research Council's Committee on Human Biomonitoring for Environmental Toxicants recently reported that data may be interpreted by a descriptive approach in which a statistical review of the data is presented to relate the results of a study population with those of a comparable or reference population (NRC, 2006) . Following this paradigm, we believe we have adequately described the NHANES PCDD/F and dioxin-like PCB serum data for the purposes outlined by the NRC. While the importance of presenting biomonitoring results for PCDD/Fs and dioxinlike PCBs is apparent, it is imperative to note that the results presented here are not intended for use in interpreting health risks or the potential health status of groups or individuals exposed to these chemicals. . Average percent and absolute difference in the mean and 95th percentile TEQ PCDD/F (a) and TEQ 17-9 (b) when including the 163 subjects with imputed congener concentrations in the data analysis. Overall, the percent difference in mean and 95th percentile estimates indicated that the results presented by Ferriby et al. (2007) and here were not considerably biased.
